Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
drospirenone + ethinylestradiol + fluoxetine
- Development stage
- Unknown
- Lead developer
- Cairo University
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Drospirenone + ethinylestradiol + fluoxetine is a combination therapy being investigated by Cairo University for the treatment of severe premenstrual syndrome (PMS). This regimen combines a fourth-generation combined oral contraceptive (COC), specifically Yasmin (containing the progestin drospirenone and the estrogen ethinylestradiol), with the selective serotonin reuptake inhibitor (SSRI) fluoxetine. Drospirenone acts as a progesterone receptor agonist to inhibit ovulation and a mineralocorticoid receptor antagonist to reduce water retention, while ethinylestradiol provides estrogenic support. Fluoxetine targets the serotonin transporter (SERT) to increase synaptic serotonin levels, addressing the neuropsychiatric symptoms of PMS. The trial evaluates whether the synergistic effect of hormonal stabilization and serotonergic modulation provides superior relief compared to monotherapy or placebo.
- Other names
- Yasmin + fluoxetineCombined oral contraceptives + fluoxetine
02
Targets
AR (Adrenergic receptors)ER (Estrogen receptor)MR (Mineralocorticoid receptor)PR (Progesterone receptor)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on drospirenone + ethinylestradiol + fluoxetine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on drospirenone + ethinylestradiol + fluoxetine.